A Clinical Stage Biotechnology Company

Caelum Biosciences is developing treatments for AL Amyloidosis, a rare and life-threatening hematologic disorder.

Have you recently been diagnosed with

AL Amyloidosis?

Caelum Biosciences has two ongoing Phase 3 clinical trials to determine if CAEL-101 has a benefit in patients with severe Cardiac AL Light Chain Amyloidosis